Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Jun 22

PMID 22719881

Citations 25

Authors

Cornelia Schuster

Hans P Eikesdal

Hanne Puntervoll

Jurgen Geisler

Stephanie Geisler

Daniel Heinrich

Anders Molven

Per E Lonning

Lars A Akslen

Oddbjorn Straume

Affiliations

Soon will be listed here.

Abstract

Background: VEGF driven angiogenesis plays a key role in cancer progression. We determined the clinical efficacy of bevacizumab monotherapy in patients with metastatic melanoma.

Methods And Findings: Thirty-five patients with metastatic melanoma in progression were enrolled in this phase II, single arm clinical trial. Each patient received bevacizumab monotherapy 10 mg/kg q14 d until intolerable toxicity or disease progression occurred. Clinical efficacy was evaluated as objective response, disease control (DC), and survival. We observed one complete (3%) and 5 partial (14%) responses. In addition, 5 patients experienced stable disease >6 months (14%) while 24 patients had progressive disease (PD, 69%), corresponding to a total DC at 6 months in 11 out of 35 patients (31%). Median progression free survival (PFS) was 2.14 months and median overall survival (OS) was 9 months (1.12-49). Seven of the 11 patients experiencing DC developed early hypertension (<2 months) compared to 3/24 of patients with PD (P = 0.001), and hypertension was associated with PFS (P = 0.005) and OS (P = 0.013).

Conclusion: Bevacizumab monotherapy demonstrated promising clinical efficacy in patients with metastatic melanoma with disease control in 31% of the patients. Induced early hypertension was a marker for clinical efficacy of bevacizumab.

Trial Registration: ClinicalTrials.gov NCT00139360.

Citing Articles

Pericytes: jack-of-all-trades in cancer-related inflammation.

Moro M, Balestrero F, Grolla A Front Pharmacol. 2024; 15:1426033.

PMID: 39086395 PMC: 11288921. DOI: 10.3389/fphar.2024.1426033.

Correlation between Efficacy and Cardiovascular Adverse Events in Patients with Advanced Solid Cancer Who Received VEGF Pathway Inhibitors: Hypertension within the First Eight Weeks Is Associated with Favorable Outcomes of Patients Treated with VEGF....

Yoshida Y, Takahashi M, Komine K, Taniguchi S, Yamada H, Sasaki K Intern Med. 2024; 64(2):177-185.

PMID: 38866528 PMC: 11802217. DOI: 10.2169/internalmedicine.3373-23.

β2-adrenergic receptor expression in patients receiving bevacizumab therapy for metastatic melanoma.

Schuster C, Akslen L, Straume O Cancer Med. 2023; 12(17):17891-17900.

PMID: 37551424 PMC: 10524038. DOI: 10.1002/cam4.6424.

Efficacy and safety of bevacizumab in patients with malignant melanoma: a systematic review and PRISMA-compliant meta-analysis of randomized controlled trials and non-comparative clinical studies.

Han X, Ge P, Liu S, Yang D, Zhang J, Wang X Front Pharmacol. 2023; 14:1163805.

PMID: 37521468 PMC: 10374288. DOI: 10.3389/fphar.2023.1163805.

Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer.

Saito Y, Takekuma Y, Komatsu Y, Sugawara M Int J Clin Oncol. 2023; 28(9):1183-1190.

PMID: 37322220 DOI: 10.1007/s10147-023-02364-4.

References

Atkins M, Lotze M, Dutcher J, Fisher R, Weiss G, Margolin K . High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999; 17(7):2105-16. DOI: 10.1200/JCO.1999.17.7.2105. View

Straume O, Akslen L . Increased expression of VEGF-receptors (FLT-1, KDR, NRP-1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma. Angiogenesis. 2004; 6(4):295-301. DOI: 10.1023/B:AGEN.0000029408.08638.aa. View

Suman V, Dueck A, Sargent D . Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis. Cancer Invest. 2008; 26(5):439-44. DOI: 10.1080/07357900801971057. View

Middleton M, Grob J, Aaronson N, Fierlbeck G, Tilgen W, Seiter S . Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000; 18(1):158-66. DOI: 10.1200/JCO.2000.18.1.158. View

Spigel D, Burris 3rd H, Greco F, Shipley D, Friedman E, Waterhouse D . Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2011; 29(18):2582-9. DOI: 10.1200/JCO.2010.30.7678. View

Straume O, Salvesen H, Akslen L . Angiogenesis is prognostically important in vertical growth phase melanomas. Int J Oncol. 1999; 15(3):595-9. DOI: 10.3892/ijo.15.3.595. View

Ratain M, Eckhardt S . Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol. 2004; 22(22):4442-5. DOI: 10.1200/JCO.2004.07.960. View

Akslen L, Puntervoll H, Bachmann I, Straume O, Vuhahula E, Kumar R . Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res. 2008; 18(1):29-35. DOI: 10.1097/CMR.0b013e3282f32517. View

Simon R, Thall P, Ellenberg S . New designs for the selection of treatments to be tested in randomized clinical trials. Stat Med. 1994; 13(5-7):417-29. DOI: 10.1002/sim.4780130506. View

10.

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

11.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

12.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

13.

Fruehauf J, Lutzky J, McDermott D, Brown C, Meric J, Rosbrook B . Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res. 2011; 17(23):7462-9. DOI: 10.1158/1078-0432.CCR-11-0534. View

14.

De Giorgi V, Grazzini M, Gandini S, Benemei S, Lotti T, Marchionni N . Treatment with β-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med. 2011; 171(8):779-81. DOI: 10.1001/archinternmed.2011.131. View

15.

Busch C, Geisler J, Lillehaug J, Lonning P . MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC. Eur J Cancer. 2010; 46(11):2127-33. DOI: 10.1016/j.ejca.2010.04.023. View

16.

Neagoe P, Lemieux C, Sirois M . Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer. J Biol Chem. 2005; 280(11):9904-12. DOI: 10.1074/jbc.M412017200. View

17.

Jain R . Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001; 7(9):987-9. DOI: 10.1038/nm0901-987. View

18.

Omholt K, Platz A, Kanter L, Ringborg U, Hansson J . NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res. 2003; 9(17):6483-8. View

19.

Barron T, Connolly R, Sharp L, Bennett K, Visvanathan K . Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol. 2011; 29(19):2635-44. DOI: 10.1200/JCO.2010.33.5422. View

20.

Ferrara N, Alitalo K . Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 1999; 5(12):1359-64. DOI: 10.1038/70928. View